| INTRODUCTION
The discovery of more potent, clinically safe, and commercially attractive new targeted drugs is the driving force at the base of medicinal chemistry research. Since a long time, our research work focused the attention on the design, synthesis, and biological evaluation of new heterocyclic compounds able to halt tumor cell proliferation ( Figure 1 compounds 1-4) . [1] [2] [3] [4] In silico approach, performed through the Virtual Lockand-Key (VLAK) protocol, [5] allowed us to select new annelated thieno-series of type 2, 3, and 4 as novel antitumor agents ( Figure 1 ). [6] These compounds, featured by a sulfur atom in the scaffold and functionalized with suitable side chains, similar to that used for the precursor series 1, [1] demonstrated in vitro antiproliferative activity, exhibiting very low toxicity and high potency. [7] [8] [9] Therefore, as a part of our ongoing search for biologically active small molecules, keeping our attention on heterocyclic ring systems, herein, we propose the synthesis, the biological screening, and the in silico insights of a new series of benzo [b] furan derivatives 5, 6, and 7 ( Figure 2 ).
The pharmaceutical interest toward these new molecules is supported by several experimental data described in the literature, [10] which assigned to the benzo[b]furan scaffold peculiar biological activities. Romagnoli and coworkers reported an interesting series of 3-arylaminobenzo[b]furans 8 as result of accurate structure-activity relationships (SAR) studies. [11] These compounds, acting on the colchicine binding site of tubulin, showed high antiproliferative activity, comparable to that of the thiophene derivatives 9a,b ( Figure 3 ). [12] | LAURIA et AL.
| EXPERIMENTAL SECTION 2.1 | Chemistry
Compounds 5-7 were completely characterized in terms of mp, 1 H and 13 C NMR, IR, and HRMS. Full details of the syntheses are provided in the Supporting information. Unless otherwise indicated, all reagents and solvents were purchased from commercial sources and used without further purification. All melting points (°C) were determined on a Büchi-Tottoli capillary apparatus and are uncorrected; IR spectra were determined in bromoform with a Jasco FT/ IR 5300 spectrophotometer. 1 H NMR and 13 C NMR spectra were, respectively, recorded, at 200 and 50.3 MHz in CDCl 3 or DMSO-d6 solution, using a Bruker AC-E series 200 MHz spectrometer. Chemical shifts values are given in ppm and referred as the internal standard to tetramethylsilane (TMS).
The following abbreviations are used: brs = broad signal, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet. The purity of all compounds screened in biological assays was determined to be >95% by HPLC/MS analysis. HRMS was obtained on an Agilent 6540 UHD accurate-mass Q-TOF spectrometer equipped with a dual AJS ESI source working in positive mode. Microanalyses were in agreement with theoretical values ±0.4%. Thin-layer chromatography was performed on precoated (0.25 mm) silica gel GF254 plates, and compounds were detected with a 254-nm UV A suspension of 5-nitro compounds 14a-f (1mmol) and 10% Pd/C (0.05g) in ethanol was subjected to hydrogenation using a Parr hydrogenation apparatus at 500 psi for 2 hr. The catalyst was removed by filtration and the filtrate was concentrated under reduced pressure. The crude was crystallized from ethanol. To a suspension of the 5a-f (1.25 mmol) and the appropriate aldehyde 15 (1.6 mmol) in dry ethanol (10 ml) was added acetic acid up to pH 4. The mixture was stirred for 30 min, and then, NaBH 3 CN (1.6 mmol) was added, continuing the stirring at room temperature for further 6-24 hr. The reaction solvent was removed under reduced pressure and the crude product was purified by chromatography column using dichloromethane/methanol 98:2 as eluent and recrystallized from ethanol. In the reactions for the synthesis of the methylimidazolyl side-chain compounds 7a-f, it was possible to isolate derivative 16 in variable yields (10%-23%).
| Biology
Propidium iodide, ribonuclease A (RNAse A), 3-(4,5-dim ethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), and DMSO were obtained from Sigma-Aldrich (St. Louis, MO, USA). RPMI, fetal bovine serum (FBS), phosphate-buffered saline (PBS), L-glutamine solution (200 mm), trypsin-EDTA solution (170,000 U/L trypsin and 0.2 g/L EDTA), and penicillin-streptomycin solution (10,000 U/ml penicillin and 10 mg/ml streptomycin) were purchased from Lonza (Verviers, Belgium).
| Cell culture
The tumor cell lines, HeLa (human epithelial cervical cancer) and MCF-7 (human epithelial breast cancer), were obtained from American Type Culture Collection (ATCC) (Rockville, MD, USA). The cells were cultured as monolayers and maintained in a humidified atmosphere with 5% CO 2 at 37°C. MCF-7 cells were grown in DMEM while HeLa cells were grown in RPMI. Both medium were supplemented with 5% FBS, 2 mm L-glutamine, 50 IU/ml penicillin, and 50 μg/ml streptomycin. The cells were routinely cultured in 75-cm 2 culture flasks and were trypsinized using trypsin-EDTA when the cells reached approximately 80% confluence. Exponentially growing cells were used for experiments.
| Antiproliferative evaluation assay
Antiproliferative activity of 3-benzoylamino-benzo[b]furan derivatives 5a-f, 6a-f, and 7a-f was evaluated by MTT assay against HeLa and MCF-7 tumor cell lines. The MTT assay is based on the protocol first described by Mossmann. [14] It is a measurement of cell metabolic activity and correlates quite well with cell proliferation. The assay was performed as previously described.
[9]
| Cell cycle analysis
Effects of the 3-benzoylamino-benzo[b]furan derivatives 7a-f exposure on cell cycle were evaluated by DNA staining with propidium iodide and flow cytometry analysis. HeLa cells were seeded on 6-well plates at a density of 130,000 cells/ well and treated 24 hr after seeding with or without various concentrations of test compounds. Following the treatments, cells were collected, washed in PBS, fixed in ice-cold 70% ethanol, and kept at −20°C. Fixed cells were centrifuged, resuspended in PBS, and stained with staining solution (20 μg/ml propidium iodide, 200 μg/ml RNAse A and Triton-X-100 in PBS) for 30 min at 37°C. The DNA contents of more than 10,000 cells were subjected to fluorescence-activated cell sorting (FACS) analysis (Coulter ® Epics ® XL™, Beckman) and the percentage of cells belonging to the different compartments of the cell cycle was determined. All experiments were performed in duplicate and reproduced at least two times.
| In silico studies
The structure similarity of the benzo[b]furans 6 and 7 with colchicine binding site binders [11] and the evidence of cell cycle arrest in G2/M phase, which is known to be a characteristic of these ligands, led to approach the in silico methods by two ways: the VLAK approach, a ligand-based method developed by us, and the IFD (induced fit docking), a structure-based one.
| VLAK protocol [5]
The protocol, described in Supporting information, starts to define the "lock model" for the studied target. A set of five ligands known colchicine binding site binders was selected ( Figure 4) . The "lock model" was used as template in the virtual screening of the title compounds. At the end, the affinity score (A%) to each tested compound is assigned. As reported in Table 1 , the A% values are in the range 0.63-0.87, assigning them a quite good affinity to colchicine binding site. [ 
| Induced fit docking (IFD)

15-17]
The crystal structure of colchicine-bound tubulin was downloaded from the PDB database (PDB code: 4O2B), and the tubulin dimer with bound colchicine (chains A and B) was extracted from the protein model. The protein was edited using Schrödinger protein preparation wizard, by adding of hydrogen for protonation of its ionisable residues, modification of tautomeric forms, and repositioning of reorientable hydrogen to yield the optimized protein-ligand complex. All the synthesized derivatives were drawn using ChemDraw. The geometry was optimized by adding hydrogen atoms, generating ionization states, neutralizing the charged groups, generating tautomers, and low-energy ring conformers. The energy-minimized structures were further used for IFD. Moreover, the crystallized ligand colchicine was redocked with the aim to evaluate the ability of IFD protocol to reproduce the experimental conformation (RMSD = 1.5 Å).
F I G U R E 4 Structures of known colchicine binding site binders
| RESULTS AND DISCUSSION
| Chemistry
In Scheme 1 is reported the general synthetic route for the preparation of 3-benzoylamino-benzo[b]furan derivatives 5-7.
1. Preparation of the benzofuran core: the 2-Fluoro-5-nitrobenzonitrile (11) was obtained through nitration of (10), using a mixture of concentrated nitric and sulfuric acids, under inert atmosphere. [13] The reactivity of the ortho-fluorine atom on substrate (11) 
| Biology
| Antiproliferative activity
The antiproliferative activity of the synthesized 3-benzoylamino-benzo[b]furan derivatives 5a-f, 6a-f, and 7a-f was evaluated on HeLa and MCF-7 tumor cell lines for 48 hr, using MTT-based cell viability assay. In Table 2 are
displayed the GI 50 values of all tested compounds, which, for an easier analysis, were divided into three main subgroups: 5-amino-benzo[b]furans 5a-f, imidazolyl side-chain compounds 6a-f, and methyl-imidazolyl side-chain derivatives 7a-f. The 5-amino-benzo[b]furan compounds 5a-f were not active or showed low activity, with GI 50 values higher than 30 μm. As clearly highlighted by the data reported in Table 2 , the insertion of the imidazolyl side-chain moiety exerted a weighty influence on the antiproliferative activity. In fact, with the exception of derivatives 6a and 6e, where the benzoyl moiety is, respectively, unsubstituted or bears a 4-trifluoromethyl substituent, the inhibition growth activity of benzo [b] furan compounds of type 6 was promising, showing GI 50 values in the low micromolar range. Within this subgroup, remarkable was the activity of the 3,4,5-trimethoxy -benzoyl-benzo[b]furan 6d on MCF-7 cell line, with a GI 50 value in the low micromolar range (3.88 μm).
On the other hand, insertion of a methyl group on the imidazole resulted in a strong increase in activity for the derivatives 7a,e,f, where the benzoyl moiety was, respectively, unsubstituted (7a versus 6a), or functionalized with 4-trifluoromethyl (7e versus 6e) and 3-chloro-4-fluoro (7f versus 6f) substituents. The cytotoxic activity was worthily interesting in the case of derivative 7f, the most active of the benzo[b]furan series, where GI 50 values on HeLa and MCF-7 tumor cell lines were, respectively, at 2.14 and 1.55 μm.
Generally, the biological activity of tested benzo[b]furan derivatives was less influenced by the nature of substituents (with both electron-withdrawing and electron-releasing effects) located on the benzoyl moiety than by the imidazolyl side chains. However, it was evident that the biological activity of the unsubstituted (5a, 6a, and 7a) and of the 4-trifluoromethyl (5e, 6e, and 7e) derivatives, with respect to the other cases, varied in peculiar way along the progression of the synthesis, from the 5-amino-benzo [b] furans to the methyl-imidazolyl side-chain derivatives. Finally, the biological screening of derivative 3-amino 16, tested in the 50-0.1 μm concentration range on both tumor cell lines, showed no activity, highlighting the crucial importance of the benzoyl moiety for the antiproliferative effect.
| Cell cycle analysis
The methyl-imidazolyl side-chain compounds 7a-f were also tested on HeLa cells, in cell cycle perturbation experiments, to evaluate their potential influence on cell cycle distribution. The flow cytometric analysis was performed after 24 hr of incubation, in order to detect the shifts in cell cycle distribution before a significant amount of cells undergoing apoptosis. The working concentrations were chosen taking into account the GI 50 values measured at 48 hr.
In Figure 5 , the percentage of cells in the respective cell cycle phase (G1, S, and G2/M) was shown, along with the 2.14 ± 0.35
1.55 ± 0.14 percentage of cells in the sub-G0/G1 (dead cells) detected by flow cytometry. Untreated HeLa cells displayed a normal diploid distribution presenting fast proliferation characteristics, with S + G2/M cell phases accounting for about 40% of the total cells (ctrl). Significant suppression of the G0/G1 phase with accumulation of cells in the G2/M was observed after cell exposure to 1× GI 50 μm of methyl-imidazolyl sidechain derivatives 7b-d,f. The effect was concentration dependent and, in our experimental conditions, treatment with a concentration of about 2× GI 50 produced deep alterations in the distribution profile. In fact, it was possible to observe a significant reduction in the cell number in all phases and a simultaneous increase in the cell population in sub-G0/G1, which are indicative of apoptotic cells. Interestingly, the unsubstituted 7a and the 4-trifluoromethyl 7e derivatives, assayed at 1× and 2× GI 50 , failed to produce significant cell cycle alterations. On the contrary, cell exposure to 2.5× GI 50 and 5× GI 50 μm of derivatives 7a,e, induced G0/G1 arrest associated with reduction in the cell number in other phases.
| In silico insights
The structure similarity of the benzo[b]furans 6, 7 with colchicine binding site binders 8 and 9, and the evidence of cell cycle arrest in G2/M phase induced by cell exposure to derivatives 7b-d,f, led to hypothesize the interference of these novel compounds with the microtubule system during the cancer cell division processes. This hypothesis 
T A B L E 4 Summary of the amino acids residues of the colchicine binding site involved in the binding
Amino acids involved in all binding poses.
F I G U R E 6
Ligand interaction maps of representative derivatives and colchicine [Colour figure can be viewed at wileyonlinelibrary.com] was studied by in silico approach, using ligand-based and structure-based methods.
In the first case, the VLAK protocol was applied with the aim to confirm the hypothesis by molecular descriptors matching through fingerprint virtual screening. As described above, the method confirmed that the titled structure posses the chemical-physical characteristic to make them potential tubulin modulators. Moreover, to investigate the binding modes of each derivative in the colchicine binding site of tubulin, in silico structure-based method was also approached. In particular, induced fit docking protocol (IFD) was approached. [15] It combines molecular dynamics, docking, and MM-GBSA scoring to predict the binding capabilities of ligands versus biological targets. The main aim of IFD protocol was to study the different binding modes of the benzofuran derivatives, taking into account the amino acid residues that are involved in the binding. The analysis of calculated values reported in Table 3 displayed that all ligand-tubulin complexes have quite good IFD scores. Particularly, it is evident as the derivatives 6 and 7 display affinity to the binding site similar to colchicine (COL) and higher than combretastatin A4 (CA4). However, when the amino acids involved in the binding complexes were analyzed, significant differences were observed.
Considering the colchicine binding site as a deep pocket placed at the α-β interface of tubulin heterodimers, it is possible to indentify three main subzones involved in the binding complexes. [18, 19] The zone 2 is located on the β subunit and accommodate the amino acids mainly involved in the colchicine binding complex. The other two zones (zone 1 and zone 3) are accessory and, respectively, located in the α subunit interface and in a deeper cavity of the β subunit. [18] In Table 4 , the amino acid residues pivotal for the inhibition of tubulin functionality are correlated with the derivatives 6a-f and 7a-f and with the two standards COL and CA4. The orange squares indicate the ligand-tubulin interactions with a distance cutoff of 3 Å. The tested benzofuran compounds showed good interactions with the amino acids ALAα180, SERα178, ILEβ318, ALAβ316, LEUβ255, Leu β248, and LYSβ254, in agreement with the IFD scores. Unlike derivatives 7a,e, the benzo[b] furans 7b-d,f present an aromatic group in contact with the CYSβ241, this feature is generally considered to be the most relevant for the identification of new antitubulin molecules, and indeed, the presence of this interaction is often used as a filtering method in docking results. [18] The above-mentioned analysis are clearly showed in Figure 6 , where the ligand interaction maps of the most representative derivatives 7b and 7e are showed and of the reference standard COL (see supplementary material for the full reported ligand interaction maps). The analysis of the binding modes of the ligands, in the colchicine binding site, showed two different poses. In fact, as depicted in Figure 7 (right, red circle) the derivatives 7b-d,f have been characterized by the position of imidazolyl side chain buried in the binding cavity, interacting with the amino acids residues critical for the inhibition of tubulin functionality. On the contrary, the analysis of the derivatives 7a,e shows this structural moiety projected outside the cavity (Figure 7 , left, red circle), involving, in the ligand-protein complex, amino acids, which are not essential for the antitubulin effect. This behavior seems consistent with the biological data. In fact, cell cycle perturbation experiment results that could suggest an antitubulin effect for the derivatives 7b-d,f were not compatible with an antimitotic mechanism in the other cases. The alternative behavior of benzofuran compounds could be justified by the presence of different substituents on the benzoyl moiety, which is the only point of diversity among the chemical moieties of the benzofuran derivatives, and for this reason determinant for the orientation in the binding poses.
| CONCLUSION
In this work, the synthesis and the biological evaluation of the new benzo[b]furan series of type 5, 6, and 7 were reported. As a general trend, the antiproliferative screening on HeLa and MCF-7 tumor cell lines underlined a significant growth inhibition effect of final imidazolyl side-chain compounds 6a-f and 7a-f. Methyl insertion on the imidazole ring resulted in a notable increase in activity. The cytotoxic effect is remarkably interesting in the case of derivative 7f, where GI 50 values on both HeLa and MCF-7 tumor cell lines are, respectively, at 2.14 and 1.55 μm. No differences were observed in the biological activity by changing the substituents on the benzoyl portion, even though the presence of this moiety was crucial for the antiproliferative effects. Indeed, the lack of activity observed through the biological screening of derivative 16 confirmed the importance of the benzoyl moiety in the benzo [b] furan series. To evaluate their potential influence on cell cycle distribution, the methyl-imidazolyl side-chain compounds 7a-f were also tested on HeLa cells, in cell cycle perturbation experiments, producing cell cycle arrest with proapoptotic effects. Their core similarity to known colchicine binding site binders led us to further study by in silico protocols the structure features as antitubulin agents. The results gained from the in silico analysis suggested that other biological targets are involved in the observed biological effects.
